
Jordi Puig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4346949/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine, 2021, 384, 417-427.	27.0	179
2	Alcohol-induced bone disease in the absence of severe chronic liver damage. Journal of Bone and Mineral Research, 1994, 9, 825-831.	2.8	68
3	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nature Communications, 2018, 9, 2739.	12.8	61
4	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy, 2014, 69, 3368-3371.	3.0	43
5	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Research, 2012, 96, 65-69.	4.1	39
6	COVIDApp as an Innovative Strategy for the Management and Follow-Up of COVID-19 Cases in Long-Term Care Facilities in Catalonia: Implementation Study. JMIR Public Health and Surveillance, 2020, 6, e21163.	2.6	39
7	High Prevalence of Sarcopenia in HIV-Infected Individuals. BioMed Research International, 2018, 2018, 1-5.	1.9	36
8	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 2015, 70, 2104-2107.	3.0	25
9	In Vivo, Non-Invasive Characterization of Human Bone by Hybrid Broadband (600-1200 nm) Diffuse Optical and Correlation Spectroscopies. PLoS ONE, 2016, 11, e0168426.	2.5	23
10	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study. PLoS ONE, 2014, 9, e84676.	2.5	11
11	Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2015, 31, 817-821.	1.1	10
12	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	3.0	9
13	Potential prescribing issues among older HIVâ€infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. British Journal of Clinical Pharmacology, 2021, 87, 1310-1317.	2.4	8
14	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. Antiviral Research, 2015, 114, 48-52.	4.1	7
15	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. BioMed Research International, 2016, 2016, 1-5.	1.9	7
16	Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp International Journal of Environmental Research and Public Health, 2022, 19, 167.	2.6	7
17	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 2452-2459.	3.0	6
18	Polymorphisms in <i>LPL</i> , <i>CETP</i> , and <i>HL</i> Protect HIV-Infected Patients from Atherogenic Dyslipidemia in an Allele-Dose-Dependent Manner. AIDS Research and Human Retroviruses, 2015, 31, 882-888.	1.1	5

Jordi Puig

#	Article	IF	CITATIONS
19	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. BioMed Research International, 2014, 2014, 1-8.	1.9	4
20	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. Future Virology, 2012, 7, 1127-1134.	1.8	3
21	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE, 2020, 15, e0238575.	2.5	3
22	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. New Microbiologica, 2015, 38, 193-9.	0.1	3
23	Association between lipid genetic and immunological status in chronically HIV-infected patients. Journal of the International AIDS Society, 2014, 17, 19555.	3.0	1
24	Title is missing!. , 2020, 15, e0238575.		0
25	Title is missing!. , 2020, 15, e0238575.		0
26	Title is missing!. , 2020, 15, e0238575.		0
27	Title is missing!. , 2020, 15, e0238575.		0
28	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with <scp>HIV</scp> . HIV Medicine, 2022, , .	2.2	0